Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

Amgen (AMGN.O) will launch its biosimilar version of Regeneron's (REGN.O) blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.